Incorporating lower grade toxicity information into dose finding designs

Author:

Iasonos Alexia1,Zohar Sarah2,O'Quigley John3

Affiliation:

1. Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

2. Biostatistics Department, INSERM, U717, Paris, France

3. INSERM, Université Paris VI, Paris, France

Abstract

Background Toxicity grades underlie the definition of a dose-limiting toxicity but in the majority of phase I designs, the information contained in the individual grades is not used. Some authors have argued that it may be more appropriate to consider a polytomous rather than dichotomous response. Purpose We investigate whether the added information on individual grades can improve the operating characteristics of the continual reassessment method. Methods We compare the original continual reassessment method design for a binary response with two stage continual reassessment method designs which make different use of lower grade toxicity information via simulations. Specifically, we study a two-stage design that utilizes lower grade toxicities in the first stage only, during the initial non-model-based escalation, and two-stage designs where lower grades are used throughout the trial via explicit models. We postulate a model relating the rates of lower grade toxicities to the rate of dose-limiting toxicity, or assume the relative rates of low-to-high grade toxicities is unknown. The designs were compared in terms of accuracy, patient allocation, and precision. Results Significant gains can be achieved when using grades in the first stage of a two-stage design. Otherwise, only modest improvements are seen when the information on grades is exploited via the use of explicit models, where the parameters are known precisely. Continual reassessment method with some use of grade information, increases the number of patients treated at the maximum tolerated dose by approximately 5%. The additional information from lower grades can lead to a small increase in the precision of our estimate of the maximum tolerated dose. Limitations Our comparisons are not exhaustive and it would be worth studying other models and situations. Conclusions Although the gains in performance were not as great as we had hoped, we observed no cases where the performance of continual reassessment method was poorer. Our recommendation is that investigators might consider using graded toxicities at the design stage.

Publisher

SAGE Publications

Subject

Pharmacology,General Medicine

Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Dose Finding in Oncology Trials Guided by Ordinal Toxicity Grades Using Continuous Dose Levels;Entropy;2024-08-14

2. Bayesian Adaptive Designs for Phase I Trials;Principles and Practice of Clinical Trials;2022

3. SPA: Single patient acceleration in oncology dose-escalation trials;Contemporary Clinical Trials;2021-06

4. Bayesian Adaptive Designs for Phase I Trials;Principles and Practice of Clinical Trials;2021

5. Bayesian Adaptive Designs for Phase I Trials;Principles and Practice of Clinical Trials;2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3